ABSTRACT
OBJECTIVE@#To evaluate the effectiveness of recombinant adenovirus p53 injection (rAd2p53) combined with cisplatin plus 5-fluorouracil regimen in treating laryngeal carcinoma.@*METHOD@#Tumour animal models were established in the back of mice with Hep-2 cell line. Recombinant adenovirus p53 injection (rAd2p53) were transduced to tumor-bearing mouse by direct intratumoral injection combine with cisplatin plus 5-fluorouracil ivgtt. The control group 1 was given recombinant adenovirus p53 injection (rAd2p53) simplex. The control group 2 was administered with cisplatin plus 5-fluorouracil ivgtt simplex. Then compare the diameters of pro-treatment with that of post-treatment and test group with controls.@*RESULT@#Tumor growth was significantly inhibited following combined rAd2p53 gene therapy with cisplatin plus 5-fluorouracil chemotherapy compared to single rAd2p53 gene therapy and cisplatin plus 5-fluorouracil chemotherapy controls.@*CONCLUSION@#Local injection of rAd2p53 combined with cisplatin plus 5-fluorouracil chemotherapy is a promising treatment to laryngeal cancer.
Subject(s)
Animals , Female , Mice , Adenoviridae , Genetics , Drug Evaluation, Preclinical , Genes, p53 , Genetic Therapy , Genetic Vectors , Laryngeal Neoplasms , Therapeutics , Mice, Inbred C3H , Neoplasms, ExperimentalABSTRACT
Objective To investigate p53 protein expression in nasopharyngeal carcinoma (NPC) and its correlation with biological behavior, p53 gene mutation and EBV infection in 43 cases of NPC. Methods Immunohistochemical staining was applied to detect p53 protein,PCR-SSCP was used to detect p53 gene mutation, and EBV infection was determined with PCR. Results The positive rate of p53 protein expression was 76 7%(33/43)in the NPC. The positive rate of p53 protein expression in stages Ⅲ and Ⅳ was significantly higher (80 6%) than that in stages Ⅰ and Ⅱ(66 6%) (P